Low riskFDA DrugClass III

Ascend dabigatran capsules recalled for failed impurity specification

Ascend Laboratories is recalling one lot of dabigatran etexilate capsules, 75 mg, 60-count, after a 12-month stability test found impurity levels outside the allowed limits. The out-of-specification results were for Impurity II, Impurity III, and total impurities. No injuries have been reported.

From the FDA notice · Read the official notice ↗ · All Ascend Laboratories recalls

What to do

  1. Talk to your pharmacist or prescriber before stopping this medicine.
  2. Check whether your capsules are Lot 25141585 with expiration date April 30, 2027, NDC 0904-7253-68, distributed by Major Pharmaceuticals, Indianapolis, IN.
  3. The notice doesn't say how to get a refund or replacement; contact Ascend Laboratories or the pharmacy where you bought it.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Dabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268, NDC 0904-7253-68.
Sold in
Nationwide
Made for
Adults (0 months and older)

This recall covers 3 products — see all of them.

Details

Units affected
924 cartons x 12 x 6 x 10 (in blister pack)
Illnesses reported
None reported
Manufactured in
135 Us Highway 202 206 Ste 15, N/A, Bedminster, NJ, United States
Classification
Class III
Recall number
D-0738-2026

In the FDA's words

Description
Dabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268, NDC 0904-7253-68. Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability Lot: 25141585, Exp. April 30, 2027. Distribution: USA Nationwide Affected quantity: 924 cartons x 12 x 6 x 10 (in blister pack)
Hazard
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

3 products in this recall

The agency lists each product separately. Check every one you might have.

More from Ascend Laboratories

See all

Related topics

Industrial chemicalsDrugsSold nationwideMore from FDA Drug